Ampersand Completes Sale of Portfolio Company Nexcelom Bioscience to PerkinElmer

WELLESLEY, Mass., June 25, 2021 /PRNewswire/ -- Ampersand Capital Partners announced today that it has completed the sale of Nexcelom Bioscience, one of its portfolio companies and a leading provider of automated cell counting solutions, to PerkinElmer for $260 million in cash.

Founded in 2003 and headquartered in Lawrence, Massachusetts, Nexcelom is the manufacturer of innovative Cellometer, Cellaca MX, and Celigo image cytometry products for cell analysis in drug discovery, development, and manufacturing workflows. In 2018, Nexcelom received an investment from Ampersand Capital Partners to support its rapid growth in aiding the discovery and development of cell, gene, and immuno-oncology therapies, virology drugs, and vaccines. Today Nexcelom has approximately 130 employees around the world based in the U.S., the UK and China and projects 2021 revenues of approximately $40 million.

"Nexcelom was founded with the goal of assisting bench scientists by automating tedious and manual cell counting processes," said Peter Li, President and CEO of Nexcelom Bioscience. "Over the past eighteen years the Company has worked closely with our customers to develop powerful tools to solve their complex challenges in rapidly developing cell-based assay and biomanufacturing markets. Ampersand's support and guidance over the past three years has been an important part of the Nexcelom story, and I feel fortunate to have had the opportunity to partner with them."

Eric Lev, General Partner of Ampersand Capital Partners, added, "When Ampersand began its partnership with co-owners Peter Li and CTO & Founder Jean Qiu about three years ago, we saw promise in Nexcelom's technology and believed we could help the company leverage its unique solutions to expand its presence in therapeutics development and manufacturing support. It has been extremely rewarding to participate in Nexcelom's sucess during our investment period, and we believe that as part of PerkinElmer Nexcelom will be well positioned to serve customers worldwide in the development of life-changing drugs and vaccines."

About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle-market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. Additional information about Ampersand is available at www.ampersandcapital.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ampersand-completes-sale-of-portfolio-company-nexcelom-bioscience-to-perkinelmer-301319774.html

SOURCE Ampersand Capital Partners

Back to news